Head-to-head evidence
apremilast vs PF-07038124
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
apremilast · Otezla
Marketed by Amgen
NCT01194219 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 844 participants, with 562 assigned to apremilast and 282 to placebo. The primary clinical endpoint was met: PASI-75 response at Week 16 was 33.1% with apremilast versus 5.3% with placebo (p<0.0001).
Next expected readout: October 2026 · NCT07432386 (registry estimate)
PF-07038124
Developed by Pfizer
NCT05375955 · Phase 2 · completed
This was a randomized, quadruple-blind, vehicle-controlled Phase 2 trial with a hard clinical primary endpoint (IGA/PGA response at week 12) and an adequate sample size (263 participants). However, the primary comparison was only partly successful: in atopic dermatitis, neither PF-07038124 0.01% (23.8% vs 11.4%, p=0.0711) nor 0.03% (21.4% vs 11.4%, p=0.1290) reached statistical significance, while in plaque psoriasis the 0.03% (37.1% vs 8.8%, p=0.0028) and 0.06% (45.5% vs 8.8%, p=0.0003) doses did. Because the primary endpoint was split across two diseases and only one cohort met it, the overall result is mixed rather than a clean success, capping the evidence at moderate.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apremilast's landscape · PF-07038124's landscape